The pharmaceutical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a greater substa